Bcl-2 expression in non-small cell lung cancers: Higher frequency of expression in squamous cell carcinomas with earlier pT status

Oncology

Volumn 56, Issue 3, 1999, Pages 259-264

  Dosaka Akita, Hirotoshi ^a   Katabami, Motoo ^c   Hommura, Humihiro ^a   Fujioka, Yasunori ^b   Katoh, Hiroyuki ^a   Kawakami, Yoshikazu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^c Iwamizawa Rousai Hospital   (Japan)

Author keywords

Bcl 2; Non small cell lung cancers; p53 protein; Prognosis; pT classification; Squamous cell carcinomas

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ADULT; ARTICLE; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA;

EID: 0032924709     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011974     Document Type: Article

References (34)

1. Ginsberg RJ, Kris MG, Armstrong JG, Ihde D, Pass HI, Glatstein EJ: Cancer of the lung; in DeVita VT, Hellman S, Rosenberg SA (ed): Cancer: Principles and Practice of Oncology, ed 4. Philadelphia, Lippincott, 1993, pp 673-758.
2. Minna JD: The molecular biology of lung cancer pathogenesis. Chest 1992;103:445S-456S.
3. Wyllie AM: Apoptosis. Br J Cancer 1993;67: 205-208.
4. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-336.
5. Korsmeyer SJ: Bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 1992;80:879-886.
6. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM: Cloning of the chromosome breakpoint of neoplastic B cells with t(14; 18) chromosome translocation. Science 1984;226: 1097-1099.
7. Ryan JJ, Prochownik E, Gottlieb CA, Apel IJ, Merino R, Nunez G, Clarke MF: c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc Natl Acad Sci USA 1994;91:5878-5882.
8. Ikegaki N, Katsumata M, Minna J, Tsujimoto Y: Expression of bcl-2 in small cell lung cacinoma cells. Cancer Res 1994;54:6-8.
9. Jiang SX, Kameya T, Sato Y, Yanase N, Yoshimura H, Kodama T: Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation. Am J Pathol 1996; 148:837-846,
10. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 1993;143:390-400.
11. Silvestrini R, Veneroni S, Daidone MG, Binini E, Boracchi P, Mezzetti M, DiFronzo G, Rilke F, Veronesi U: The bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994;86:499-504.
12. Lu QL, Lucas ES, Thomas JA: Bcl-2 protooncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma. Int J Cancer 1993;53:29-35.
13. World Health Organization: Histological Typing of Lung Tumors, ed 2. Geneva, World Health Organization, 1981, pp 25-26.
14. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ: Lung; in Manual for Staging of Cancer, ed 4. Chicago, American Joint Committee on Cancer, 1992, pp 115-122.
15. Harada M, Dosaka-Akita H, Miyamoto H, Kuzumaki N, Kawakami Y: Prognostic significance of the expression of ras oncogene product in non-small cell lung cancer. Cancer 1992;69: 72-77.
16. Fujino M, Dosaka-Akita H, Harada M, Hiroumi H, Kinoshita I, Akie K, Kawakami Y: Prognostic significance of p53 and ras p21 expression in nonsmallcell lung cancer. Cancer 1995; 76:2457-2463.
17. Dosaka-Akita H, Hu S, Fujino M, Harada M, Kinoshita I, Xu H, Kuzumaki N, Kawakami Y, Benedict WF: Altered Rb protein expression in non-small cell lung cancer: Its synergistic effects with altered ras and p53 protein status on prognosis. Cancer 1997;79:1329-1337.
18. Pezzella F, Tse AGD, Cordell JL, Pulford KAF, Gatter KC, Mason DY: Expression of the bcl-2 oncogene protein is not specific for the 14; 18 chromosomal translocation. Am J Pathol 1990;137:225-232.
19. Kaplan EL, Meier P: Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-481.
20. Gehan EA: A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 1965;52:203-223.
21. Harrell FE Jr: The PHGLM procedure; in Hastings RP (ed): Supplementary Library User's Guide. Cary, SAS Institute, 1986, pp 437-466.
22. Katabami M, Dosaka-Akita H, Honma K, Kimura K, Fujino M, Uchida Y, Mikami H, Ohsaki Y, Kawakami Y, Kikuchi K: p53 and Bcl-2 expression in pneumoconiosis-related precancerous lesions and lung cancers: Frequent and preferential p53 expression in pneumoconiotic bronchiolar dysplasias. Int J Cancer 1998;75:504-511.
23. Nakamura T, Nomura S, Sakai T, Nariya S: Expression of bcl-2 oncoprotein in gastrointestinal and uterine carcinomas and their premalignant lesions. Hum Pathol 1997;28:309-315.
24. Shiseki M, Kohno T, Nishikawa R, Sameshima Y, Mizogichi H, Yokota J: Frequent allelic losses on chromosomes 2q, 18q, and 22q in advanced non-small cell lung cancers. Cancer Res 1994;54:5643-5648.
25. Nagatake M, Osada H, Kondo M, Uchida K, Nishio M, Shimokata K, Takahashi T, Takahashi Ta: Aberrant hypermethylation at the bcl-2 locus at 18q21 in human lung cancers. Cancer Res 1996;56:1886-1891.
26. Ritter JH, Dresler CN, Wick MR: Expression of bcl-2 protein in stage T1N0M0 non-small cell lung carcinoma. Hum Pathol 1995;26: 1227-1232.
27. Tormanen U, Eerola AK, Rainio P, Vahakagas K, Soini Y, Sormunen R, Bloigu R, Lehto V, Paako P: Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. Cancer Res 1995;55:5595-5602.
28. Ohsaki Y, Toyoshima E, Fujiuchi S, Matsui H, Hirata S, Miyokawa N, Kubo Y, Kikuchi K: bcl-2 and p53 protein expression in non-small cell lung cancers: Correlation with survival time. Clin Cancer Res 1996;2:915-920.
29. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC, Mason DY: bcl-2 protein in non-small cell lung carcinoma. N Engl J Med 1993;329:690-694.
30. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, Basolo F, Bevilacqua G: Bcl-2 protein: A prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 1995;71:1003-1007.
31. Anton RC, Brown RW, Younes M, Gondo MM, Stephenson MA, Cagle PT: Absence of prognostic significance of bcl-2 immunopositivity in non-small cell lung cancer: Analysis of 427 cases. Hum Pathol 1997;28:1079-1082.
32. Pastorino U, Andreola S, Tagliabue E, Pezzella F, Incarbone M, Sozzi G, Buyse M, Menard S, Pierotti M, Rilke F: Immunocytochemical markers in stage I lung cancer: Relevance to prognosis. J Clin Oncol 1997;15:2858-2865.
33. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumor suppressor gene: Clue to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-4878.
34. Hansen RS, Braithwaite AW: The growth-inhibitory function of p53 is separable from transactivation, apoptosis and suppression of transformation by Ela and Ras. Oncogene 1996;13:995-1007.